Brief report: Hepatic dysfunction as a complication of adenosine deaminase deficiency

New England Journal of Medicine

Volumn 334, Issue 21, 1996, Pages 1367-1371

  Bollinger, Mary E ^a,c   Arredondo Vega, Francisco X ^b   Santisteban, Ines ^b   Schwarz, Kathleen ^a   Hershfield, Michael S ^b   Lederman, Howard M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; PEGADEMASE;

ADENOSINE DEAMINASE DEFICIENCY; ARTICLE; CASE REPORT; COMBINED IMMUNODEFICIENCY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER DYSFUNCTION; MALE; NEWBORN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADENOSINE DEAMINASE; BASE SEQUENCE; DNA, COMPLEMENTARY; HEPATITIS; HUMANS; INFANT, NEWBORN; JAUNDICE, NEONATAL; MALE; MOLECULAR SEQUENCE DATA; MUTATION; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 0029879147     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199605233342104     Document Type: Article

References (38)

1. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosinedeaminase deficiency in two palients with severely impaired cellular immunity. Lancet 1972;2:1067-9.
2. Hirschhorn R. Adenosine deaminase deficiency. Immunodefic Rev 1990;2: 175-98.
3. Hershfield MS, Mitchell BS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver CR, Beaudet AL. Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 7th ed. Vol. 2. New York: McGraw-Hill, 1995:1725-68.
4. Rosen FS, Cooper MD, Wedgwood RJP. The primary immunodeficiencies. N Engl J Med 1995;333:431-40.
5. Hirschhorn R, Papageorgiou PS, Kesarwala HH, Taft LT. Amelioration of neurologic abnormalities after "enzyme replacement" in adenosine deaminase deficiency. N Engl J Med 1980;303:377-80.
6. Wakamiya M, Blackburn MR, Jurecic R, et al. Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. Proc Natl Acad Sci U S A 1995;92:3673-7.
7. Migchielsen AAJ, Breuer ML, van Roon MA, et al. Adenosine-deaminasedeficient mice die perinatally and exhibit liver-cell degeneration, atelectasis and small intestinal cell death. Nat Genet 1995;10:279-87.
8. Wiginton DA, Adrian GS, Mutton JJ. Sequence of human adenosine deaminase cDNA including the coding region and a small intron. Nucleic Acids Res 1984;12:2439-46.
9. Wiginton DA, Kaplan DJ, States JC, et al. Complete sequence and structure of the gene for human adenosine deaminase. Biochemistry 1986;25:8234-44.
10. Santisteban I, Arredondo-Vega FX, Kelly S, et al. Novel splicing, missense, and deletion mutations in seven adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency disease: contribution of genotype to phenotype. J Clin Invest 1993;92:2291-302.
11. Arredondo-Vega FX, Santisteban I, Kelly S, Schlossman CM, Umetsu DT, Hershfield MS. Correct splicing despite mutation of the invariant first nucleotide of a 5′ splice site: a possible basis for disparate clinical phenotypes in siblings with adenosine deaminase deficiency. Am J Hum Genet 1994;54: 820-30.
12. Santisteban I, Arredondo-Vega FX, Kelly S, et al. Four new adenosine deaminase mutations, altering a zinc-binding histidine, two conserved alanines, and a 5′ splice site. Hum Mutat 1995;5:243-50.
13. Santisteban I, Arredondo-Vega FX, Kelly S, et al. Three new adenosine deaminase mutations that define a splicing enhancer and cause severe and partial phenotypes: implications for evolution of a CpG hotspot and expression of a transduced ADA cDNA. Hum Mol Genet 1995;4:2081-7.
14. Arredondo-Vega FX, Kurtzberg J, Chaffee S, et al. Paradoxical expression of adenosine deaminase in T cells cultured from a patient with adenosine deaminase deficiency and combined immunodeficiency. J Clin Invest 1990; 86:444-52.
15. Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987;316:589-96.
16. Weinberg K, Hershfield MS, Bastian J, et al. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase. J Clin Invest 1993;92:596-602.
17. Hershfield MS, Chaffee S, Sorensen RU. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy. Pediatr Res 1993;33:Suppl:S42-S48.
18. Hershfield MS. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum Mutai 1995;5:107-12.
19. Idem. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin Immunol Immunopathol 1995;76:S228-S232.
20. Akeson AL, Wiginton DA, Slates JC, Perme CM, Dusing MR, Hutton JJ. Mutations in the human adenosine deaminase gene that affect protein structure and RNA splicing. Proc Natl Acad Sci USA 1987;84:5947-51.
21. Markert ML, Norby-Slycord C, Ward FE. A high proportion of ADA point mutations associated with a specific alanine-to-valine substitution. Am J Hum Genet 1989;45:354-61.
22. Akeson AL, Wiginton DA, Dusing MR, States JC, Hutton JJ. Mutant human adenosine deaminase alleles and their expression of transfection into fibroblasts. J Biol Chem 1988;263:16291-6.
23. Ratech H. Greco MA, Gallo G, Rimoin DL, Kamino H, Hirschhorn R. Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations. Am J Pathol 1985;120:157-69.
24. Benveniste P, Cohen A. p53 Expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc Natl Acad Aci U S A 1995;92:8373-7.
25. Hershfield MS. Apparent suicide inactivation of human lymphoblast S-adenosylhomocystcine hydrolase by 2′-deoxyadenosine and adenine arabinoside: a basis for direct toxic effects of analogs of adenosine. J Biol Chem 1979;254:22-5.
26. Kredich NM, Martin DV Jr. Role of S-adenosylhomocysteine in adenosine mediated toxicity in cultured mouse T lymphoma cells. Cell 1977;12:931 8.
27. Hershfield MS, Kredich NM. Resistance of an adenosine kinase-deficient human lymphoblastoid cell line to effects of deoxyadenosine on growth, S-adenosylhomocysteine hydrolase inactivation, and dATP accumulation. Proc Natl Acad Sci U S A 1980;77:4292-6.
28. Wolos JA, Frondorf KA, Davis GF, Jarvi ET, McCarthy JR, Bowlin TL. Selective inhibition of T cell activation by an inhibitor of S-adenosyl-L-homocysteine hydrolase. J Immunol 1993;150:3264-73.
29. Wolos JA, Frondorf KA, Esser RE. Immunosuppression mediated by an inhibitor of S-adenosyl-L-homocysteine hydrolase: prevention and treatment of collagen-induced arthritis. J Immunol 1993;151:526-34.
30. Kredich NM, Hershfield MS. S-adenosylhomocysteine toxicity in normal and adenosine kinase-deficient lymphoblasts of human origin. Proc Natl Acad Sci U S A 1979;76:2450-4.
31. Wainfan E, Dizik M, Slender M, Christman JK. Rapid appearance of hypomethylated DNA in livers of rats fed cancer-promoting, methyl-deficient diets. Cancer Res 1989;49:4094-7.
32. Chandar N, Lombardi B, Locker J. c-myc Gene amplification during hepatocarcinogenesis by a choline-devoid diet. Proc Natl Acad Sci U S A 1989; 86:2703-7.
33. Poirier LA. Methyl group deficiency in hepatocarcinogenesis. Drug Metab Rev 1994;26:185-99.
34. Hirschhorn R. Adenosine deaminase deficiency: molecular basis and recent developments. Clin Immunol Immunopathol 1995;76:S219-S227.
35. 1-Antitrypsin deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D. eds. The metabolic and molecular bases of inherited disease. 7th ed. Vol. 3. New York: McGraw-Hill, 1995:4125-58.
36. O'Reilly RJ, Keever CA, Small TN, Brochstein J. The use of HLA-non-identical T-cell-depleted marrow for transplants for correction of severe combined immunodeficiency disease. Immunodetic Rev 1989;1:273-309.
37. Stephan JL, Vlekova V, Le Deist F, et al. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J Pediatr 1993;123:564-72.
38. Dror Y, Gallagher R, Wara DW, et al. Immune reconstitution in severe combined immunodeficiency disease after lectin-treated, T-cell-depleted haplocompatible bone marrow transplantation. Blood 1993;81:2021-30.